GlassScriptPhysician profile
Srikanth Nadella
NPI 1740599109
$4,072.78
in general payments reported to CMS, 2019-2025
27 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.34 · 2020: $144 · 2021: $384 · 2022: $449 · 2023: $1,252 · 2024: $722 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,067.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $806.08 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $573.31 | 2023-2025 | Freestyle Libre 3, Absolute Pro |
| Lilly USA, LLC | $495.89 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Medtronic, INC. | $482.80 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $331.06 | 2020-2024 | Farxiga |
| Dexcom, INC. | $268.18 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Insulet Corporation | $175.79 | 2023-2025 | Omnipod |
| Mannkind Corporation | $122.75 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $119.37 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $112.02 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.31 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $63.41 | 2023 | Korlym |
| Clarus Therapeutics INC. | $52.99 | 2021 | |
| Tandem Diabetes Care, INC. | $52.60 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $49.63 | 2023-2025 | Repatha, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $45.01 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $43.21 | 2021-2023 | |
| Ibsa Pharma INC. | $30.75 | 2023-2024 | Tirosint, Tirosint, Licart |
| Averitas Pharma INC. | $27.03 | 2025 | Qutenza |
| Amneal Pharmaceuticals LLC | $24.53 | 2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $21.06 | 2023 | Strensiq |
| Allergan, INC. | $19.20 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $18.80 | 2024 | |
| Madrigal Pharmaceuticals | $17.11 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $15.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2019 | |
| Amryt Pharma Holdings LTD | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Nadella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.